Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been given an average rating of "Moderate Buy" by the six analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $10.80.

A number of research analysts recently weighed in on RGLS shares. Oppenheimer reissued an "outperform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. StockNews.com raised Regulus Therapeutics to a "sell" rating in a research note on Tuesday, September 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Tuesday, October 8th.

Regulus Therapeutics Stock Up 7.3 %

Shares of RGLS traded up $0.11 during midday trading on Tuesday, reaching $1.61. 1,411,279 shares of the stock were exchanged, compared to its average volume of 1,300,048. Regulus Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.79. The firm has a 50 day simple moving average of $1.59 and a 200-day simple moving average of $1.88. The company has a market cap of $105.41 million, a price-to-earnings ratio of -1.28 and a beta of 1.62.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.17). Research analysts expect that Regulus Therapeutics will post -0.8 earnings per share for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several institutional investors have recently modified their holdings of RGLS. NEA Management Company LLC acquired a new stake in Regulus Therapeutics in the 1st quarter valued at $18,627,000. RA Capital Management L.P. acquired a new stake in Regulus Therapeutics in the 1st quarter valued at $18,000,000. CVI Holdings LLC acquired a new stake in Regulus Therapeutics in the 1st quarter valued at $4,050,000. Vanguard Group Inc. boosted its stake in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company's stock valued at $2,132,000 after buying an additional 453,784 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Regulus Therapeutics in the 2nd quarter valued at $352,000. Institutional investors and hedge funds own 92.38% of the company's stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.